How AI Search is Reshaping the Digital Ecosystem of the Pharmaceutical Industry: The Profound Impact of Google AI Overviews

When AI Becomes the Gatekeeper of Pharmaceutical Information

In 2026, Google Search's AI Overviews feature already covers 75% of pharmaceutical-related queries. This represents a significant increase from 50% the previous year, signaling an acceleration in the search engine's transformation from a "link directory" to an "AI answer engine." For the pharmaceutical industry, this is not merely a technological upgrade—it is rewriting the fundamental rules of how patients and healthcare professionals discover drug information, and how pharmaceutical companies build brand awareness.

From Linear Funnel to AI-Mediated Fragmented Discovery

Traditionally, pharmaceutical marketing relied on a clear linear conversion funnel: users search for keywords, click on top-ranking websites, obtain information, and potentially take action. The advent of AI Overviews has disrupted this path. When a user types "X drug side effects" or "latest treatment for Y disease" into the search box, Google's Gemini model directly generates a summary synthesizing information from multiple sources. Users often obtain key answers without needing to click any links.

According to EVERSANA INTOUCH's 2026 report, even when a pharmaceutical company's website is cited as a source in the AI summary, click-through rates still decline significantly. However, on the flip side, brands cited by AI experience a substantial increase in click-through rates—a polarized scenario: either become an AI-recognized authoritative source, or disappear from users' view.

Fan-out Queries: AI's Silent Discovery Layer

A key new concept introduced in this year's report is "fan-out queries." When a user submits a search request, AI dynamically breaks that query into multiple contextual sub-queries to gather and synthesize information. For example, if a user searches for "new migraine drug," AI may simultaneously search for "migraine pathology mechanism," "recent clinical trial results," "common side effects," "patient forum discussions," and more.

This means that if pharmaceutical companies optimize only for the explicit keywords users enter, they may completely miss the implicit queries AI uses to construct its answers. A brand's visibility in AI search depends on its performance across these "fanned-out" subtopics. This is a dimension that traditional SEO has never touched—AI no longer passively matches keywords; it actively decides what information is worth presenting.

Why Is This Happening Now?

The explosion of AI Overviews is no accident. Since 2023, the maturity of generative AI has enabled search engines to generate credible summaries at very low cost. Facing competitive pressure from emerging AI search products like Perplexity and ChatGPT Search, Google has accelerated the embedding of AI into its core search. For the pharmaceutical industry, this timing coincides with the continued growth of digital health demands—patients increasingly rely on online channels to learn about diseases and treatment options, a trend further reinforced by the proliferation of telemedicine after the pandemic.At the same time, pharmaceutical companies’ own digitalization processes are accelerating. Dispersed information sources such as social media, physician communities, and patient forums have led users to expect comprehensive answers within a single interface. AI Overviews precisely meets this need, but it also shifts attention away from brand-owned websites to AI-generated summary pages.

Structural Change: SEO/GEO as Infrastructure

In the past, search engine optimization (SEO) was considered a branch of digital marketing. Now it must become core infrastructure for pharmaceutical companies. Josie Black points out that SEO/GEO should no longer be treated as an isolated channel tactic, but rather "embraced as the foundational architecture of discoverability." This means technical optimization, off-site brand building (including social media, Reddit, YouTube, link building), high-quality content, and exceptional user experience must work in synergy.

This change has long-term structural implications. The rise of AI search weakens the traditional ranking logic of "search engine results pages" (SERPs), replacing it with a comprehensive assessment of content quality and authority. Pharmaceutical companies need to rethink their content strategy: not only producing information for human readers but also ensuring that content can be understood, cited, and trusted by AI models.

Overall Impact on the Pharmaceutical Marketing Ecosystem

The proliferation of AI Overviews is breaking down traditional departmental silos in pharmaceutical marketing. Search is no longer an independent function; it must work closely with PR, content strategy, social media, and digital marketing. A brand’s performance in AI search results depends on its reputation and information consistency across the entire digital ecosystem.

More profoundly, AI search is changing the nature of "discovery." Users no longer need to actively browse multiple websites; AI completes the information filtering for them. This lowers the barrier to information access but also increases the risk of spreading misinformation or bias—especially in the pharmaceutical domain, where accuracy and safety are paramount. Pharmaceutical companies must proactively participate in AI search’s "knowledge graph" to ensure their information is correctly cited.

Looking Ahead

As AI search continues to evolve, the pharmaceutical industry will face deeper transformations. AI may not only summarize existing information but also generate personalized health advice, posing new challenges for regulatory compliance and ethics. Meanwhile, in an AI-dominated discovery world, brand influence will shift from "click volume" to "citation count" and "trustworthiness." Companies that can adapt to this new paradigm will seize the advantage in the next decade of digital health.

Google AI Overviews is not a one-time algorithm update but a structural turning point in how information is accessed. For the pharmaceutical industry, it’s time to prepare for a world where AI serves as the primary intermediary.